Macrocyclic insulin-degrading enzyme (IDE) inhibitors and uses thereof
Macrocyclic compounds that specifically inhibit insulin degrading enzyme (IDE) are provided. Pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, polymorphs, tautomers, isotopically enriched forms, and prodrugs of the macrocyclic IDE inhibitors are also described. Pharmaceutical compositions are also provided. In vivo and in vitro methods of using the IDE inhibitor, and pharmaceutical compositions comprising the IDE inhibitor, for example, for the inhibition of IDE in a subject exhibiting aberrant IDE activity, impaired insulin signaling, or insulin resistance, for example, a subject having diabetes, are also provided.
1. A method of treating a disease, disorder, or condition associated with aberrant insulin degrading enzyme (IDE) activity, impaired insulin signaling, or insulin resistance, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (V):
or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, polymorph, tautomer, or isotopically enriched form thereof,
wherein:
is a single or double C—C bond, wherein when is a double C—C bond, then indicates that the adjacent C═C double bond is in a cis or trans configuration;
R 1 is hydrogen; substituted or unsubstituted aliphatic; or substituted or unsubstituted heteroaliphatic;
R 2 is hydrogen; halogen; substituted or unsubstituted aliphatic; or substituted or unsubstituted heteroaliphatic;
R 5 is substituted or unsubstituted aliphatic; substituted or unsubstituted heteroaliphatic; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; substituted or unsubstituted amino; —C(═O)—N(R J ) 2 ; —C(═O)—OR J ; —C(═O)—SR J ; or —CH 2 —C(═O)N(R J ) 2 ; wherein each occurrence of R J is independently hydrogen; a protecting group; substituted or unsubstituted aliphatic; substituted or unsubstituted heteroaliphatic; substituted or unsubstituted acyl; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl; or two R J groups are joined to form a substituted or unsubstituted heterocyclic group; optionally wherein R 5 further comprises a label, resin, or therapeutic agent attached thereto;
each instance of R E , R F , R G , R H , and R I is independently hydrogen; substituted or unsubstituted acyl; a nitrogen protecting group; substituted or unsubstituted aliphatic; or substituted or unsubstituted heteroaliphatic;
n is 0 or an integer between 1 and 10, inclusive; and
m is an integer between 1 and 5, inclusive.
2. The method of claim 1 , wherein the compound is of formula (VI):
or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, polymorph, tautomer, or isotopically enriched form thereof.
3. The method of claim 1 , wherein the compound is of formula (VIII):
or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, polymorph, tautomer, or isotopically enriched form thereof.
4. The method of claim 1 , wherein R 1 is hydrogen, —CH 3 , —CH 2 —CH 2 —C(═O)—NH 2 , —CH 2 —CH 2 —CH 2 —NH—C(═NH)—NH 2 , —(CH 2 ) p -cyclohexyl, —(CH 2 ) p -cyclopentyl, —(CH 2 ) p -cyclobutyl, —(CH 2 ) p -cyclopropyl, —(CH 2 ) p -phenyl, or —CH 2 CH 2 CH 2 CH 2 —NH 2 , wherein each occurrence of p is independently 0 or an integer between 1 and 10 inclusive.
5. The method of claim 1 , wherein R 1 is hydrogen, —CH 3 , —CH 2 —CH 2 —C(═O)—NH 2 , —CH 2 —CH 2 —CH 2 —NH—C(═NH)—NH 2 , —CH 2 -cyclohexyl, —CH 2 -cyclopropyl, or —CH 2 CH 2 CH 2 CH 2 —NH 2 .
6. The method of claim 1 , wherein R 2 is hydrogen.
7. The method of claim 1 , wherein R 2 is —(CH 2 ) q —CH 3 , wherein q is 0 or an integer between 1 and 10 inclusive.
8. The method of claim 1 , wherein R 5 is —C(═O)NH 2 or —CH 2 C(═O)NH 2 .
9. The method of claim 1 , wherein is a double bond.
10. The method of claim 9 , wherein the double bond is in trans-configuration.
11. The method of claim 9 , wherein the double bond is in cis-configuration.
12. The method of claim 1 , wherein n is 1.
13. The method of claim 1 , wherein m is 4.
14. The method of claim 1 , wherein the compound is selected from the group consisting of:
(wherein X is —CH 2 CH 2 —),
wherein C is:
and pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, polymorphs, tautomers, and isotopically enriched forms thereof.
15. The method of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, polymorph, tautomer, or isotopically enriched form thereof.
16. The method of claim 1 , wherein the compound is administered in an amount effective to reduce IDE activity in the subject to less than about 50% as compared to the IDE activity in the absence of the compound.
17. The method of claim 1 , wherein the IDE activity is plasma IDE activity and/or pancreas IDE activity.
18. The method of claim 1 , wherein the subject exhibits impaired insulin signaling or insulin resistance.
19. The method of claim 1 , wherein the disease, disorder, or condition is diabetes.
20. The method of claim 1 , wherein the disease, disorder, or condition is metabolic syndrome.
21. A method of inhibiting the activity of insulin-degrading enzyme (IDE), the method comprising contacting the IDE with an effective amount of a compound of Formula (V):
or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, polymorph, tautomer, or isotopically enriched form thereof,
wherein:
is a single or double C—C bond, wherein when is a double C—C bond, then indicates that the adjacent C═C double bond is in a cis or trans configuration;
R 1 is hydrogen; substituted or unsubstituted aliphatic; or substituted or unsubstituted heteroaliphatic;
R 2 is hydrogen; halogen; substituted or unsubstituted aliphatic; or substituted or unsubstituted heteroaliphatic;
R 5 is substituted or unsubstituted aliphatic; substituted or unsubstituted heteroaliphatic;
substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; substituted or unsubstituted amino; —C(═O)—N(R J ) 2 ; —C(═O)—OR J ; —C(═O)—SR J ; or —CH 2 —C(═O)N(R J ) 2 ; wherein each occurrence of R J is independently hydrogen; a protecting group; substituted or unsubstituted aliphatic; substituted or unsubstituted heteroaliphatic; substituted or unsubstituted acyl; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl; or two R J groups are joined to form a substituted or unsubstituted heterocyclic group; optionally wherein R 5 further comprises a label, resin, or therapeutic agent attached thereto;
each instance of R E , R F , R G , R H , and R I is independently hydrogen; substituted or unsubstituted acyl; a nitrogen protecting group; substituted or unsubstituted aliphatic; or substituted or unsubstituted heteroaliphatic;
n is 0 or an integer between 1 and 10, inclusive; and
m is an integer between 1 and 5, inclusive.